Cancer research
Scientists at Agios Pharmaceuticals have made a groundbreaking discovery in the field of cancer metabolism, establishing that the mutated IDH1 gene has a novel enzyme activity consistent with a cancer-causing gene, or oncogene. This breakthrough reveals that the mutated form of IDH1 produces a metabolite, 2-hydroxyglutarate (2HG), which may contribute
Scientists
In a recent study, researchers from the United States have made significant discoveries about the underlying causes of posterior fossa syndrome, a condition characterized by cerebellar dysfunction, oromotor/oculomotor apraxia, emotional lability, and mutism in patients after infratentorial injury. The study, conducted at St. Jude Children's Research Hospital,
Scientists
Scientists from Hanyang University have made a breakthrough in understanding the molecular mechanism underlying the oncogene-induced cellular death process. Their study published in Molecular Cancer Research reveals that retroviral expression of oncogenic H-ras induces cell death in a caspase-independent manner in normal cells. The researchers found that inhibition of c-Jun
Cancer
Researchers in Greece have developed a replication-defective recombinant adenovirus (RAd) vector expressing human CD40 ligand (RAd-hCD40L) which shows direct anti-proliferative and pro-apoptotic effects on malignant cells. The study, published in Cancer Gene Therapy, found that transduction of CD40-positive bladder, cervical, and ovarian carcinoma cell lines with RAd-hCD40L potently inhibits their
Cancer
Researchers in the United States have found that the loss of p21(WAF1) promotes adenovirus replication and more effective cell killing, offering potential therapeutic benefits for cancer treatment. A study published in Cancer Gene Therapy reveals that knocking down p21(WAF1) in cancer cells enhances the replication and killing of
Cancer
Researchers in the United States have identified Axl as a potential therapeutic target in cancer, with their study shedding light on its role in tumor growth, metastasis, and angiogenesis. The investigation, published in Oncogene, reveals that Axl dysregulation contributes to the pathogenesis of several human cancers. The study used RNAi
Cancer
Researchers in Shanghai, People's Republic of China, have developed an oncolytic adenovirus, Ad.sp-E1A((Delta 24))-IL-24, which exhibits an excellent antitumor effect in vitro for human nasopharyngeal, liver, lung, and cervical carcinoma cell lines. The virus, driven by the survivin promoter, achieves nearly complete inhibition of NCI-H460
Scientists
Researchers in the Netherlands conducted a phase I dose escalation study to evaluate the safety and tolerability of telatinib, a tyrosine kinase inhibitor that targets vascular endothelial growth factor receptor (VEGFR) -2, VEGFR-3, platelet-derived growth factor receptor-beta, and c-Kit. The study involved 53 patients with solid tumors who were refractory
Scientists
Scientists in the United States have made significant findings in their study on the role of protein phosphatase 5 (PP5) in protecting neurons against amyloid-beta toxicity in Alzheimer's disease. According to E. Sanchez-Ortiz and colleagues from Purdue University, PP5 plays a crucial role in inactivating mitogen-activated protein kinase
Cancer
Recent research from the University of Leicester, United Kingdom, has unveiled the cancer chemopreventive properties of cyanidin-3-glucoside (C3G), an anthocyanin component found in fruits and berries. The study, led by T.H. Marczylo, found that C3G possesses significant pharmacological activity in mouse models of carcinogenesis, with the potential to target
Cancer
Lung cancer is a leading cause of cancer death worldwide, with a high incidence of metastasis making it a formidable challenge for treatment. Novel and effective treatments are urgently needed, and researchers have been exploring cancer-specific targeted gene therapy as a potential solution. Recent data from a study conducted in
Cancer
Recent research from the Medical University of South Carolina has shed new light on the potential of TRAIL, a protein involved in immunosurveillance, as a cancer therapy. The study, published in the Journal of Urology, found that TRAIL can induce apoptosis in cancer cells, but not in normal cells. However,
